Recent FDA Committee Vote Could Speed Multiple Mye

An FDA committee voted unanimously last month to approve a new clinical endpoint, minimal residual disease, when evaluating proposed drugs to treat multipl

Related Keywords

Miami ,Florida ,United States ,Maryalice Stelter Stevenson ,Gerald Marti ,C Ola Landgren ,Seanm Devlin ,National Cancer Institute ,National Heart ,National Institutes Of Health ,Drug Administration ,Blood Institute ,Memorial Sloan Kettering Cancer Center ,University Of Miami Miller School Medicine ,Myeloma Research Institute ,Sylvester Comprehensive Cancer Center ,Miami Miller School ,National Institutes ,Memorial Sloan Kettering Cancer ,Evaluating Minimal Residual Disease ,